uniQure N.V. (NASDAQ:QURE) Receives Consensus Recommendation of “Moderate Buy” from Analysts

uniQure N.V. (NASDAQ:QURE) has earned a consensus rating of “Moderate Buy” from the fourteen research firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, ten have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $66.0833.

QURE has been the topic of several recent analyst reports. HC Wainwright decreased their price target on uniQure from $110.00 to $70.00 and set a “buy” rating on the stock in a research note on Tuesday, November 4th. The Goldman Sachs Group reduced their price objective on uniQure from $56.00 to $38.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 4th. UBS Group set a $95.00 target price on uniQure in a research note on Thursday, September 25th. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, August 2nd. Finally, Cantor Fitzgerald raised their price target on shares of uniQure from $47.00 to $80.00 and gave the company an “overweight” rating in a research note on Thursday, September 25th.

Insider Activity at uniQure

In other uniQure news, Director Jack Kaye sold 38,810 shares of the firm’s stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $30.34, for a total value of $1,177,495.40. Following the sale, the director owned 20,439 shares in the company, valued at $620,119.26. This trade represents a 65.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Robert Gut sold 31,434 shares of the company’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $27.26, for a total transaction of $856,890.84. Following the transaction, the director owned 40,145 shares of the company’s stock, valued at $1,094,352.70. This trade represents a 43.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 314,560 shares of company stock worth $12,362,568 in the last 90 days. 4.79% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On uniQure

Institutional investors and hedge funds have recently bought and sold shares of the company. Aberdeen Group plc grew its holdings in shares of uniQure by 24.2% during the second quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company’s stock worth $38,345,000 after purchasing an additional 535,163 shares during the last quarter. Jennison Associates LLC bought a new position in uniQure in the 2nd quarter valued at approximately $1,952,000. Y Intercept Hong Kong Ltd acquired a new stake in uniQure during the 2nd quarter worth approximately $872,000. Cubist Systematic Strategies LLC acquired a new stake in uniQure during the 1st quarter worth approximately $2,562,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in uniQure during the 1st quarter worth approximately $152,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Stock Performance

Shares of uniQure stock opened at $30.84 on Wednesday. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53. The company has a market cap of $1.69 billion, a PE ratio of -7.87 and a beta of 0.59. The company has a 50 day moving average of $42.55 and a 200-day moving average of $24.50. uniQure has a 1-year low of $5.50 and a 1-year high of $71.50.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.53). uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $4.46 million. As a group, equities research analysts forecast that uniQure will post -3.75 earnings per share for the current fiscal year.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.